00000nam 2200000zi 4500 9.916714 CaOODSP 20221130092217 m o d f cr cn||||||||| 221028t20222022onc o f000 0 eng d 9780660460291 CaOODSP eng rda CaOODSP n-cn--- HP5-148/2022E-PDF Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults. Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, 2022. ©2022 1 online resource (3 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Recommandations sur l'utilisation chez les adultes du vaccin de rappel à ARNm Spikevax bivalent BA.4/5 (50 mcg) de Moderna contre la COVID-19 : résumé des mises à jour du Comité consultatif national de l'immunisation (CCNI) du 3 novembre 2022. Cover title. "Pub.: 220546." "On November 3, 2022, Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals 18 years of age and older"--Overview, page 3. COVID-19 (Disease) Vaccination Canada. COVID-19 (Disease) Vaccination Government policy Canada. Public Health Agency of Canada, issuing body. Canada. National Advisory Committee on Immunization, issuing body. Résumé des mises à jour du Comité consultatif national de l'immunisation (CCNI) du 3 novembre 2022 : (CaOODSP)9.916716 PDF 824 KB https://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-148-2022-eng.pdf HTML N/A https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/summary-national-advisory-committee-immunization-november-3-2022-recommendations-use-moderna-spikevax-bivalent-mrna-50-mcg-covid-19-booster-vaccine-adults.html 220546